TY  - CHAP
M1  - Book, Section
TI  - Chapter 225. Dapsone
A1  - Sago, Joni G.
A1  - Hall, Russell P.
A2  - Goldsmith, Lowell A.
A2  - Katz, Stephen I.
A2  - Gilchrest, Barbara A.
A2  - Paller, Amy S.
A2  - Leffell, David J.
A2  - Wolff, Klaus
PY  - 2012
T2  - Fitzpatrick's Dermatology in General Medicine, 8e
AB  - |PrintDapsone  at  a  GlanceDapsone  (4,4’-diaminodiphenylsulfone)  is  classified  as  sulfonamide  but  has  unique  pharmacologic  properties.Diseases  with  consistent  response  to  dapsone  are  dermatitis  herpetiformis,  erythema  elevatum  diutinum,  linear  immunoglobulin  A  dermatosis/chronic  bullous  disease  of  childhood  and  bullous  eruption  of  systemic  lupus  erythematosus.Diseases  with  sporadic  response  to  dapsone  encompass  a  wide  spectrum  and  are  as  diverse  as  collagen  vascular/autoimmune  diseases  and  acne.  In  these  diseases,  dapsone  can  be  used  as  a  corticosteroid  sparing  agent.A  unifying  feature  of  responsive  diseases  is  neutrophilic  and  eosinophilic  granulocytes.Dapsone  is  also  effective  in  certain  infections  such  as  leprosy,  actinomycetoma,  or  rhinosporidiosis.Adverse  effects  are  hemolysis  and  methemoglobulinemia.  Glucose-6-phosphate  dehydrogenase  (G6PD)  level  should  be  obtained  before  beginning  dapsone  treatment.  Dapsone  should  only  be  given  with  great  caution  to  patients  with  G6PD  deficiency.Other  adverse  effects  are  neuropathy,  a  mononucleosis-like  hypersensitivity  syndrome  termed  the  sulfone  syndrome,  and  agranulocytosis.  
SN  - 
PB  - The McGraw-Hill Companies
CY  - New York, NY
Y2  - 2024/04/24
UR  - accessmedicine.mhmedical.com/content.aspx?aid=56098794
ER  -